The S&P 500 Index ($SPX ) (SPY ) on Monday closed down by -0.53%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -0.90%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.36%....
The S&P 500 Index ($SPX ) (SPY ) today is down by -0.59%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.40%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.97%. December E-mini...
WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...
Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis Successfully completed drug-drug interaction...
WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...
Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets New preclinical data show that...
SION-719 is the first NBD1 stabilizer being evaluated in people living with cystic fibrosis Topline data expected in mid-2026 WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics,...
Raymond James analyst maintained a Buy rating on Sionna Therapeutics, Inc. today and set a price target of $45.00. The company’s shares closed yesterday at $30.91.Elevate Your Investing Strategy: Take...
WALTHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...